Roughly a year ago, Insilico Medicine announced that it had dosed the first patient in a phase 1 study of INS018_055, an AI-discovered, first-in-class small molecule inhibitor. Now, the company has progressed to the next stage, launching a phase 2 study for the drug candidate. Insilico, a founding member of NVIDIA Inception, developed its AI…
Quantum-inspired power could brighten drug discovery
In the realm of drug discovery, the Harvard-educated chemist Nick Paras, Ph.D. compares the early stages of identifying new compounds to a game of Zelda, in which a player at times must navigate through dark rooms and solve puzzles to progress. Similarly, medicinal chemists and biochemists too must traverse the vast, often obscure landscape of…
How AI and the cloud can transform R&D workflows and fuel collaboration
The rise of cloud-based systems and AI-assisted analysis has dramatically transformed the landscape of scientific research and collaboration. One striking example is the mRNA company Moderna, which used the cloud to develop and deliver its first clinical batch of a COVID-19 vaccine candidate for phase 1 trials in a mere 42 days after the initial…
Generative AI could boost biopharma R&D productivity by billions, according to McKinsey
Generative AI stands to add trillions of dollars of value to the world economy, according to a recent McKinsey report. The consultancy noted that about three-quarters of the value of generative AI spans four areas — customer operations, marketing and sales, software engineering and R&D. The latter could see a 12% annual lift in global…
Navigating generative AI in drug discovery and data analysis: Seizing the opportunity and avoiding pitfalls
Along with predictive AI, generative AI is emerging as a promising tool in drug discovery. Thanks in part to the rise of ChatGPT, interest in the technology in drug discovery is on the upswing. In March, a preprint appeared examining the potential to use generative AI to enable de novo antibody design. Also this year,…